STOCK TITAN

IGC Pharma Inc Stock Price, News & Analysis

IGC NYSE

Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.

IGC Pharma Inc (NYSE American: IGC) is a clinical-stage biotechnology leader pioneering AI-driven cannabinoid therapies for Alzheimer’s disease, chronic pain, and neurological disorders. This page provides investors and researchers with timely updates on the company’s pharmaceutical advancements, clinical trial progress, and strategic initiatives.

Access comprehensive coverage of IGC’s investigational drug pipeline, including IGC-AD1 for Alzheimer’s-related agitation currently in Phase 2 trials. Stay informed about cutting-edge research integrating artificial intelligence to optimize therapeutic development and diagnostic precision.

Explore updates across key areas: clinical trial milestones, regulatory developments, research partnerships, and product launches from the Holiby™ wellness brand. Our curated news collection ensures you never miss critical updates about IGC’s dual focus on pharmaceutical innovation and consumer health solutions.

Bookmark this page for verified information on IGC Pharma’s advancements in cannabinoid science, AI applications in drug discovery, and market-moving developments. Check regularly for authoritative reporting on one of biotech’s most innovative players.

Rhea-AI Summary

IGC Pharma (NYSE American:IGC) has expanded its Phase 2 clinical trial for IGC-AD1, a drug candidate targeting agitation in Alzheimer's disease patients, by adding a new site at the Lynn Health Science Institute (LHSI) in Oklahoma City.

The CALMA trial, designed as a randomized, double-blind, placebo-controlled study, will be led by Principal Investigator Dr. Carl Griffin at the new site. The trial aims to evaluate IGC-AD1's safety and efficacy in addressing one of Alzheimer's most challenging symptoms - agitation, which often leads to earlier institutionalization and increased caregiver stress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
-
Rhea-AI Summary

IGC Pharma (NYSE American:IGC) reported Q1 fiscal 2026 financial results, highlighting progress in its Phase 2 CALMA trial for Alzheimer's disease treatment. Revenue increased 21% to $328,000 compared to Q1 FY2025. The company reduced its net loss to $1.6 million ($0.02 per share) from $2.3 million year-over-year.

Notable achievements include expansion of trial sites across North America for IGC-AD1, a cannabinoid-based treatment for Alzheimer's agitation, advancement of MINT-AD AI platform for early Alzheimer's detection, and extension of an undrawn $12 million credit facility with O-Bank. The company successfully reduced SG&A expenses by 28% to $1.2 million and raised $3.5 million through private placements and ATM offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
-
Rhea-AI Summary

IGC Pharma (NYSE:IGC) announced promising preclinical results for two Alzheimer's disease treatments. Their lead candidate IGC-M3, a novel small molecule, demonstrated significant activity against multiple Alzheimer's pathology drivers, including over 90% prevention of beta-amyloid fibril formation and superior antioxidant performance compared to vitamin C.

The company is pursuing a dual-strategy approach with IGC-AD1, a cannabinoid-based therapy currently in Phase 2 clinical trials for Alzheimer's-related agitation, and IGC-M3, targeting multiple disease mechanisms in preclinical development. IGC-AD1 utilizes THC to address agitation affecting up to 76% of Alzheimer's patients, while IGC-M3 shows promise in disease modification through multiple pathways including amyloid reduction, metal ion regulation, and inflammation control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
Rhea-AI Summary

IGC Pharma (NYSE American:IGC) has announced promising preclinical data for its investigational molecule IGC-M3 in the treatment of Alzheimer's disease. The in vitro studies demonstrate that IGC-M3 targets multiple biological mechanisms central to Alzheimer's pathology through four key actions:

The compound has shown ability to inhibit amyloid aggregation, promote disassembly of amyloid aggregates, neutralize reactive oxygen species, and reduce pro-inflammatory signaling in cellular models. In SH-SY5Y human neuronal cells, IGC-M3 demonstrated neuroprotective effects, while in BV2 microglial cells, it reduced Aβ42-induced activation and decreased pro-inflammatory markers.

The company plans to advance IGC-M3 to in vivo studies to evaluate its potential efficacy and safety in animal models, aiming to develop a disease-modifying treatment for Alzheimer's.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
-
Rhea-AI Summary

IGC Pharma (NYSE American: IGC) announced it will present three scientific posters at the 2025 Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31, 2025. The presentations will showcase the company's AI-driven innovations in Alzheimer's disease research.

The posters will highlight: 1) MINT-AD, an AI foundation model trained on 100+ global datasets for Alzheimer's risk assessment, 2) Research on using large language models to predict cognitive scores without brain scans or blood biomarkers, and 3) An AI-powered drug discovery pipeline focusing on GLP-1 and CB1 targets for Alzheimer's treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences AI
-
Rhea-AI Summary

IGC Pharma (NYSE American:IGC), a clinical-stage biopharmaceutical company focused on Alzheimer's disease, announced that its Principal Scientist, Dr. Jagadeesh Rao, has received the Best Researcher Award at the 11th Annual World Neuroscientist Awards. The recognition comes from an international panel of experts, highlighting his 15+ years of scientific leadership in neuroscience research.

Dr. Rao's work has been crucial in advancing IGC-AD1, the company's investigational drug currently in Phase 2 trials for treating agitation in Alzheimer's patients. His selection came from a competitive pool of over 360 nominations across 125 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none
Rhea-AI Summary

IGC Pharma (NYSE American:IGC) has unveiled MINT-AD, an AI-powered diagnostic platform designed to identify individuals at high risk of Alzheimer's disease before symptoms manifest. The Multimodal Interpretable Transformer for Alzheimer's platform integrates diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics to generate risk profiles and cognitive decline forecasts.

The company plans to launch a beta version in Fiscal 2026 for pilot evaluation with academic and clinical partners. MINT-AD aims to address the global diagnostic gap, where over 400 million people may have Alzheimer's-related pathology before clinical symptoms appear. The platform is designed to extend cognitive diagnostics beyond specialized facilities to general practices and underserved populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.39%
Tags
AI
-
Rhea-AI Summary

IGC Pharma (NYSE American: IGC) has released its Fiscal Year 2025 financial results and operational highlights, marking significant progress in its Alzheimer's disease research and development programs. The company's lead asset, IGC-AD1, demonstrated positive interim results in its Phase 2 CALMA trial, showing significant reduction in agitation and sleep disturbances in Alzheimer's patients.

Financial results show revenue of $1.2 million in FY2025, slightly down from $1.3 million in FY2024. The company reduced its net loss to $7.1 million ($0.09 per share) from $13 million ($0.22 per share) in FY2024. SG&A expenses decreased by 35% to $4.4 million, while R&D expenses were $3.7 million. The company raised $4.64 million through equity placements and ATM offerings.

Key operational achievements include expanding clinical trial sites across North America, advancing the development of MINT-AD (an AI-based diagnostic tool), and winning two PREPARE Challenge awards. The company plans to complete the CALMA Phase 2 trial, launch a second Phase 2 study for IGC-AD1's disease-modifying effects, and deploy a beta version of MINT-AD in FY2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
-
Rhea-AI Summary

IGC Pharma (NYSE American:IGC) has scheduled a conference call and webcast for Monday, June 30, 2025, at 11:00 a.m. ET to discuss their fiscal year 2025 operational progress and financial results for the period ended March 31, 2025. The financial results will be released before market opening on the same day.

Shareholders and investors can participate via phone by dialing (888) 506 0062 (US) or (973) 528 0011 (International) using access code 370284. A webcast will be available, and a replay can be accessed until July 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
conferences earnings
Rhea-AI Summary
IGC Pharma has expanded its Phase 2 CALMA clinical trial for IGC-AD1, a treatment for agitation in Alzheimer's dementia, to a new site at Tekton Research in Yukon, Oklahoma. The expansion, led by board-certified neurologist Dr. David McCoy as principal investigator, aims to diversify the trial population and address regional healthcare disparities in the Oklahoma City metropolitan area. Tekton Research brings extensive experience in conducting clinical trials across various therapeutic areas including Alzheimer's disease, migraine, and vaccines. The site is now accepting patient enrollments, with interested participants able to contact Tekton Research directly through their Yukon facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none

FAQ

What is the current stock price of IGC Pharma (IGC)?

The current stock price of IGC Pharma (IGC) is $0.3734 as of August 25, 2025.

What is the market cap of IGC Pharma (IGC)?

The market cap of IGC Pharma (IGC) is approximately 33.2M.
IGC Pharma Inc

NYSE:IGC

IGC Rankings

IGC Stock Data

33.18M
83.23M
8.45%
18.55%
1.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
POTOMAC